Mark McDade is Chairman of the Aimmune Board of Directors and Executive Vice President and Chief Operating Officer of UCB, a global biopharmaceutical company focusing on neurology and immunology treatment and research. At UCB, Mr. McDade leads worldwide geographic operations, established brands, technical operations and business development. Previously, Mr. McDade served as CEO and as a Director of PDL Biopharma. He was also CEO of Signature Bioscience; Founder, Chief Operating Officer, President and a Director of Corixa Corporation; and Chief Operating Officer of Boehringer Mannheim Therapeutics, the bio-pharmaceutical division of Corange.
Earlier in his career, Mr. McDade held several positions at Sandoz Ltd., including business development, product management and general management. He serves on the Boards of Directors of Five Prime Therapeutics and Dermira. Mr. McDade received an MBA from the Harvard Business School and a BA in History from Dartmouth College.